BioSpace News Archive

Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its Second Quarter 2020 Financial Results on Monday, August 3, 2020, at 4:30pm Eastern Time. The call will be webcast and may be accessed at Pacific Biosciences’ website at: https://investor.pacificbiosciences.com/ . Date: August 3, 2020 Time: 4:30pm ET Listen via Internet: https://investor.pacificbiosciences.com/ Toll-

The measles, mumps, and rubella vaccines market is observing significant growth due to high incidence of pneumococcal infections.

Lysogene, a Phase 3 gene therapy platform company targeting central nervous system diseases, provides H1 2020 Business update.

Calliditas Therapeutics AB announced that it has reorganized its management team.

Advanced semiconductor-based DNA synthesis platform creates precise mutant libraries for engineering antibodies for in vitro diagnostic applications

Dr. Michelle McMurry-Heath, the president and CEO of the Biotechnology Innovation Organization (BIO), released a statement today warning that an executive order to adopt foreign price controls on certain prescription medicines could “cripple” companies working to eradicate COVID-19 and lead to less patient access to lifesaving treatments.

“In H1 2020, we have worked diligently to maintain operations through the COVID-19 pandemic. We have adapted our working routines and practices to ensure the continuing safety of our employees as a top priority.

Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) filed its financial and operating results on Friday, July 24 for the fourth quarter and the year ended March 31, 2020

The Health Literacy Experts Provide Trusted Health Information to Health Care Providers on the Frontlines

MetVital, Inc., today announces that the National Institute of Health, National Institute of Neurological Disorders and Stroke has accepted MetVital’s AEO drug candidate for screening to evaluate its potential for epilepsy treatment